26 May 2020 - - US-based life sciences company Bio-Techne (NASDAQ: TECH) and German workflow solutions and automation provider Leica Biosystems have launched, in Europe, the CE-IVD marked RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform, the companies said.

The combination of Bio-Techne's RNAscope and Leica's BOND-III will provide pathologists access to an unprecedented number of leading applications to support their diagnostics labs.

Tissue-based diagnostics are growing in globally and there is a demand for high throughput, streamlined workflows that enable visualisation of genomic expression at the individual cell level.

RNAscope, a leading RNA ISH technology, improves on traditional ISH methodologies through higher target sensitivity and specificity.

This combined with the automation of the Leica BOND-III, will optimize and streamline the applications in diagnostic labs.

The RNAscope In Situ Hybridization Detection Kit and Probes are a robust technology that identifies RNA expression patterns and localization at the single cell level with spatial and morphologic context.

The RNAscope technology is highly sensitive, and specific due to its double Z probe design, resulting in an extremely high signal-to-noise ratio of staining in various tissues types, allowing diagnostic pathologists to visualize, localize, and quantify biomarker expression simultaneously.

Building on its legacy of excellence in advanced staining technology and pathology processes the new BOND-III makes it easier for labs to quickly and consistently deliver complete cases to pathologists.

With optimal patient care depending on an accurate and timely diagnosis, the latest advance to the BOND-III stainer incorporates a unique set of productivity innovations to support pathology labs' drive for procedural efficiency and diagnostic confidence.

Bio-Techne Corp. (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies.

Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow.

These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments.

Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate test for prostate cancer diagnosis.

These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases.

They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

With thousands of products in its portfolio, Bio-Techne generated approximately USD 714m in net sales in fiscal 2019 and has over 2,200 employees worldwide.

Leica Biosystems is in workflow solutions and automation, integrating each step in the workflow.